EP3897607A4 - Therapeutische verfahren und zusammensetzungen zur behandlung von krebs unter verwendung von 6,8-bis-benzylthio-octansäure und einem autophagen inhibitor - Google Patents

Therapeutische verfahren und zusammensetzungen zur behandlung von krebs unter verwendung von 6,8-bis-benzylthio-octansäure und einem autophagen inhibitor Download PDF

Info

Publication number
EP3897607A4
EP3897607A4 EP19901283.2A EP19901283A EP3897607A4 EP 3897607 A4 EP3897607 A4 EP 3897607A4 EP 19901283 A EP19901283 A EP 19901283A EP 3897607 A4 EP3897607 A4 EP 3897607A4
Authority
EP
European Patent Office
Prior art keywords
benzylthio
bis
compositions
treating cancer
octanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19901283.2A
Other languages
English (en)
French (fr)
Other versions
EP3897607A1 (de
Inventor
Timothy S. PARDEE
Sanjeev LUTHER
Paul Bingham
Zuzana Zachar
Shawn D. STUART
Robert G.L. Shorr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornerstone Pharmaceuticals Inc
Original Assignee
Rafael Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rafael Pharmaceuticals Inc filed Critical Rafael Pharmaceuticals Inc
Publication of EP3897607A1 publication Critical patent/EP3897607A1/de
Publication of EP3897607A4 publication Critical patent/EP3897607A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19901283.2A 2018-12-20 2019-12-20 Therapeutische verfahren und zusammensetzungen zur behandlung von krebs unter verwendung von 6,8-bis-benzylthio-octansäure und einem autophagen inhibitor Withdrawn EP3897607A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782928P 2018-12-20 2018-12-20
US201962793667P 2019-01-17 2019-01-17
US201962834475P 2019-04-16 2019-04-16
US201962854599P 2019-05-30 2019-05-30
PCT/US2019/067759 WO2020132397A1 (en) 2018-12-20 2019-12-20 Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor

Publications (2)

Publication Number Publication Date
EP3897607A1 EP3897607A1 (de) 2021-10-27
EP3897607A4 true EP3897607A4 (de) 2022-08-24

Family

ID=71101607

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19901283.2A Withdrawn EP3897607A4 (de) 2018-12-20 2019-12-20 Therapeutische verfahren und zusammensetzungen zur behandlung von krebs unter verwendung von 6,8-bis-benzylthio-octansäure und einem autophagen inhibitor

Country Status (8)

Country Link
EP (1) EP3897607A4 (de)
JP (1) JP2022515171A (de)
KR (1) KR20210105923A (de)
CN (1) CN113543778A (de)
AU (1) AU2019404339A1 (de)
CA (1) CA3121929A1 (de)
TW (1) TW202038931A (de)
WO (1) WO2020132397A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023070101A1 (en) * 2021-10-22 2023-04-27 Cornerstone Pharmaceuticals, Inc. Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718914C2 (ru) * 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANGELIQUE V ONORATI ET AL: "Targeting autophagy in cancer", CANCER, AMERICAN CANCER SOCIETY , PHILADELPHIA , PA, US, vol. 124, no. 16, 19 April 2018 (2018-04-19), pages 3307 - 3318, XP071177994, ISSN: 0008-543X, DOI: 10.1002/CNCR.31335 *
ANONYMOUS: "Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma", BLOOD, 1 January 2016 (2016-01-01), XP055741754, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/128/22/4163/114147/Phase-I-Dose-Escalation-Study-of-Cpi-613-in> [retrieved on 20201020] *
KING C LEE ET AL: "Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613", ANNALS OF TRANSLATIONAL MEDICINE, 1 September 2014 (2014-09-01), China, pages 91 - 1014, XP055679530, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205874/pdf/atm-02-09-91.pdf> [retrieved on 20200325], DOI: 10.3978/j.issn.2305-5839.2014.05.08 *
PASQUIER BENOIT: "Autophagy inhibitors", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 73, no. 5, 11 December 2015 (2015-12-11), pages 985 - 1001, XP035801809, ISSN: 1420-682X, [retrieved on 20151211], DOI: 10.1007/S00018-015-2104-Y *
REBECCA ANDERSON BS ET AL: "PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613", HEMASPHERE, 1 June 2018 (2018-06-01), XP055722056, Retrieved from the Internet <URL:https://rafaelpharma.com/wp-content/uploads/2018/07/Rafael-Abstract-EHA-2018-Poster-AML_Aging.pdf> [retrieved on 20200812] *
See also references of WO2020132397A1 *
T. S. PARDEE ET AL: "A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies", CLINICAL CANCER RESEARCH, vol. 20, no. 20, 27 August 2014 (2014-08-27), US, pages 5255 - 5264, XP055721419, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-1019 *
ZUZANA ZACHAR ET AL: "Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, vol. 89, no. 11, 19 July 2011 (2011-07-19), pages 1137 - 1148, XP019965329, ISSN: 1432-1440, DOI: 10.1007/S00109-011-0785-8 *

Also Published As

Publication number Publication date
JP2022515171A (ja) 2022-02-17
WO2020132397A1 (en) 2020-06-25
EP3897607A1 (de) 2021-10-27
TW202038931A (zh) 2020-11-01
AU2019404339A1 (en) 2021-06-24
CA3121929A1 (en) 2020-06-25
CN113543778A (zh) 2021-10-22
KR20210105923A (ko) 2021-08-27

Similar Documents

Publication Publication Date Title
EP3947715A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3894392A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3826666A4 (de) Zusammensetzungen und verfahren zur behandlung von nrp2-assoziierten erkrankungen
EP3983445A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3934652A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von krankheiten
EP3938354A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3890725A4 (de) Zusammensetzungen zur behandlung von hauterkrankungen
EP3934615A4 (de) Zusammensetzungen und verfahren zur behandlung von akne
EP3775263A4 (de) Zusammensetzungen und verfahren zur behandlung von akne
EP3908601A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3968785A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3969597A4 (de) Zusammensetzungen und verfahren zur behandlung von atpase-vermittelten erkrankungen
EP3931336A4 (de) Zusammensetzungen und verfahren zur behandlung von laminopathien
EP3737379A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselkrankheiten
EP4025590A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3965896A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4085053A4 (de) Behandlung von krebs mit cdk12/13-inhibitoren
EP3793566A4 (de) Zusammensetzungen und verfahren zur reduktion von spliceopathie und behandlung von rna-dominanzstörungen
EP4003351A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3849591A4 (de) Verfahren und zusammensetzungen zur behandlung von hauterkrankungen
EP3773585A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4017490A4 (de) Verbindungen und verfahren zur behandlung von oxalat-assoziierten erkrankungen
EP3781148A4 (de) Therapeutische verfahren und zusammensetzungen zur behandlung von prostatakrebs mit 6,8-bis-benzylthio-octansäure
EP3983014A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3930705A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220722

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220718BHEP

Ipc: A61P 35/02 20060101ALI20220718BHEP

Ipc: A61P 35/00 20060101ALI20220718BHEP

Ipc: A61K 31/155 20060101ALI20220718BHEP

Ipc: A61K 31/7004 20060101ALI20220718BHEP

Ipc: A61K 31/4184 20060101ALI20220718BHEP

Ipc: A61K 31/4706 20060101ALI20220718BHEP

Ipc: A61K 31/20 20060101AFI20220718BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230221